Analysts at Oppenheimer began coverage on shares of Gamida Cell (NASDAQ:GMDA) in a research report issued on Wednesday. The firm set an “outperform” rating and a $15.00 price target on the stock. Oppenheimer’s target price suggests a potential upside of 50.75% from the company’s current price.
Other equities analysts have also recently issued research reports about the company. BMO Capital Markets assumed coverage on Gamida Cell in a report on Wednesday. They issued a “buy” rating and a $19.00 price target on the stock. Royal Bank of Canada assumed coverage on Gamida Cell in a report on Tuesday. They issued an “outperform” rating and a $20.00 price target on the stock.
Gamida Cell stock traded up $0.11 during mid-day trading on Wednesday, hitting $9.95. The stock had a trading volume of 1,248 shares, compared to its average volume of 51,555. Gamida Cell has a 12 month low of $7.99 and a 12 month high of $10.60.
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant.
Read More: No Load Funds
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.